MarginsXMarginsX
Home › Markets › Health Care › MRKR

Marker Therapeutics Inc. (MRKR)

MRKR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.8286
-4.76% on the day
Market cap
$13.8M
Nano cap
Revenue · 2025
$3.5M
-46.2% on 2024
Net income · 2025
-$12.2M
-343.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1094038/000110465926031274/0001104659-26-031274-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMRKR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001094038
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$3.5M
Net income-$12.2M
Operating income-$12.9M
Net margin-343.0%
Operating margin-363.5%
Revenue growth-46.2%
Cash$16.1M
Total assets$19.1M
P/E (computed)Net income was not positive
P/S (computed)3.9×

Warning signs

Cash runway
13.9 months
$11.3M cash at June 30, 2026
Share count, 1 year
+28.9%
2025-08-04 to 2026-08-07 · +89.3% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt regarding the Company's ability to continue as a going concern."
10-Q 2026-08-14
Cash and burn$11.3M cash; operating cash flow -$2.4M a quarter.Report 2026-06-30
Shares outstanding16,673,127 (2026-08-07); 12,938,910 a year earlier; 8,809,260 three years earlier.Cover page 2026-08-07
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Houston, Texas, United States; changed auditors 1 time in 24 months8-K 4.01 2025-08-12
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$1.8M-$3.7M$11.3MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
$752K-$3.2M-$1.4M$14.9MNo debt tags$3.9M10-Q 2026-05-15
Q4 2025
2025-12-31
$1.1M-$1.7M-$1.9M$16.1MNo debt tags$3.5M10-K 2026-03-18
Q3 2025
2025-09-30
$1.2M-$2.0M-$2.7M$17.6MNo debt tags$4.7M10-Q 2025-11-13
Q2 2025
2025-06-30
$861K-$4.0M-$1.9M$10.5MNo debt tags$5.4M10-Q 2025-08-14
Q1 2025
2025-03-31
$349K-$4.4M-$5.5M$13.7MNo debt tags$5.7M10-Q 2026-05-15
Q4 2024
2024-12-31
$2.3M-$3.8M-$4.7M$19.2MNo debt tags$6.6M10-K 2026-03-18
Q3 2024
2024-09-30
$1.9M-$2.3M$1.2M$9.0MNo debt tags$5.4M10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B72025-08-05
Latest annual report10-K2026-03-18
Latest quarterly / interim10-Q2026-11-16
Latest current report
FORM 8-K
8-K2026-10-19
Latest proxyDEFA14A2026-03-20

Source: SEC EDGAR submissions feed, 905 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.2%
1 month-5.4%
3 months-21.6%
Year to date-41.6%
1 year-2.2%
From 52-week high-60.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ALLRAllarity Therapeutics Inc.$0.8752-8.24%$13.9M
NEUPNeuphoria Therapeutics Inc.$2.48-2.75%$13.4M
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M
CTXRCitius Pharmaceuticals Inc.$0.5276-1.40%$14.5M
CMMBChemomab Therapeutics Ltd. American Depositary Share$1.62+5.88%$13.0M
TVRDTvardi Therapeutics Inc.$1.10-6.78%$14.7M
KYNBKyntra Bio Inc.$3.20-8.31%$13.0M
ACTUActuate Therapeutics Inc.$0.2680-7.59%$14.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier